- Home
- NXN vs RFL Comparison
NXN vs RFL Comparison
Compare NXN & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | NXN | RFL |
|---|---|---|
| Founded | 1992 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Real Estate |
| Sector | Finance | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.6M | 54.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NXN | RFL |
|---|---|---|
| Price | $12.07 | $1.16 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 9.7K | ★ 198.0K |
| Earning Date | 01-01-0001 | 12-11-2025 |
| Dividend Yield | ★ 4.23% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.24 | N/A |
| Revenue | N/A | ★ $1,029,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $48.42 | ★ N/A |
| Revenue Growth | N/A | ★ 47.63 |
| 52 Week Low | $10.64 | $1.12 |
| 52 Week High | $12.45 | $3.19 |
Technical Indicators
Market Signals| Indicator | NXN | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 46.54 | 39.29 |
| Support Level | $12.02 | $1.21 |
| Resistance Level | $12.18 | $1.28 |
| Average True Range (ATR) | 0.09 | 0.11 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 60.88 | 8.46 |
Price Performance
Historical ComparisonAbout NXN Nuveen New York Select Tax-Free Income Portfolio
Nuveen NY Select Tax-Free Income Port is a diversified closed-end management investment company. Its investment objective are to provide current income exempt from regular federal and New Jersey income tax, and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.
About RFL Rafael Holdings Inc. Class B
Rafael Holdings Inc is a holding company with interests in clinical and early-stage pharmaceutical companies. Its primary focus is to expand its investment portfolio through opportunistic investments including therapeutics, which address high unmet medical needs. Through the companies it has invested in, the company is focused on; developing Trappsol Cyclo its clinical program, developing instruments to advance minimally invasive surgeries, preclinical cancer metabolism research operations, and developing pharmaceutical-grade technology Unlokt for third-party cannabis manufacturers. It also holds and manages commercial real estate assets in Jerusalem, Israel. The company's reportable segments are; Infusion Technology, which derives maximum revenue, Healthcare, and Real Estate.